Voyager, Transition Bio’s small molecule drug pact; CRISPR Therapeutics ends work on a CAR-T therapynews2025-11-11T15:41:06+00:00November 11th, 2025|Endpoints News|
AnaptysBio reports Phase 2 fail in ulcerative colitis; Lyell’s CAR-T licensing dealnews2025-11-10T16:14:00+00:00November 10th, 2025|Endpoints News|
Sana suspends work on allogeneic CAR-T; Biokin eyes $387M raise in Hong Kongnews2025-11-07T15:27:39+00:00November 7th, 2025|Endpoints News|
Dyne changes plans for DM1 drug again; Dynavax licenses Vaxart’s Covid vaccinenews2025-11-06T15:43:37+00:00November 6th, 2025|Endpoints News|
Lilly partners with AI biologics company; Amgen ends gastric cancer studynews2025-11-05T15:27:32+00:00November 5th, 2025|Endpoints News|
Incyte, Prelude ink rare blood cancer pact; Merck takes back rights to Prometheus assetnews2025-11-04T15:31:15+00:00November 4th, 2025|Endpoints News|
TScan to cut a third of its staff; Iovance advances Amtagvi in lung cancernews2025-11-03T15:43:34+00:00November 3rd, 2025|Endpoints News|
4DMT licenses eye gene therapy to Otsuka in Asia-Pacific; Arcus’ $250M offeringnews2025-10-31T14:45:46+00:00October 31st, 2025|Endpoints News|
Boehringer licenses preclinical program from Kyowa Kirin; Savara makes a royalty dealnews2025-10-30T14:18:35+00:00October 30th, 2025|Endpoints News|
Recursion gets $30M from Roche; Chinese siRNA biotech to go public in Hong Kong news2025-10-29T14:32:31+00:00October 29th, 2025|Endpoints News|
